Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review

Abstract Background The administration of second-line or subsequent immune checkpoint inhibitors (ICIs) in previously treated patients with advanced solid cancers has been clinically investigated. However, previous clinical trials lacked an appropriate primary endpoint for efficacy assessment. This...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Jingqiu Li, Xiaoding Zhou, Lei Wu, Jiabao Ma, Yan Tan, Songke Wu, Jie Zhu, Qifeng Wang, Qiuling Shi
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2025-02-01
Saila:	BMC Cancer
Gaiak:	Early efficacy endpoint Immune checkpoint inhibitor Advanced solid cancer Progression-free survival Objective response Overall survival
Sarrera elektronikoa:	https://doi.org/10.1186/s12885-025-13712-0
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!